IBLHL reports FY26 revenue of ~PKR 4.6Bn up 7% YoY, PAT at ~PKR 220Mn up 6% YoY
IBL HealthCare Limited (IBLHL) - FY26 Corporate Briefing Takeaways
Key highlights and strategic updates from the flashnote issued by Taurus Securities Limited on Tuesday, November 3, 2026.
Report Overview
IBL HealthCare Pakistan (IBLHL) undertook a major strategic refocus in FY26, narrowing its diverse portfolio into two primary verticals: Nutrition and Medical & Surgical Disposables (MSD), while discontinuing non-core portfolios.
Financial Performance & Highlights
Key financial figures reported for FY26 include:
- Revenue: Totaled ~PKR 4.6Bn, reflecting a 7% YoY increase compared to ~PKR 4.3Bn in FY25. Excluding discontinued portfolios (~PKR 312Mn in FY25), continuing revenue grew ~15% YoY.
- Profit After Tax (PAT): Surged to ~PKR 220Mn (EPS: ~PKR 2.24) from ~PKR 208Mn (EPS: ~PKR 2.11), marking a 6% YoY growth.
- Gross Margins: Improved to ~36% in FY26 from 33% in FY25, with gross profit growing ~14% YoY to ~PKR 1.6Bn due to a better product mix and local production emphasis.
- Marketing & Distribution Expenses: Increased by ~17% YoY to ~PKR 1,006Mn (up from PKR 858Mn in FY25) due to investments in brand-building for the Nutrition portfolio.
Business Catalysts & Strategy
MSD served as the primary growth engine, expanding ~13% to ~PKR 2.3Bn and contributing nearly half of total revenue. Nutrition grew ~2% on a reported basis. IBLHL is expanding its Nutrition segment through partnerships with global brands like Mead Johnson and Nestle Health Sciences, alongside launching new in-house brands (Uptake and Elevate).
Risks & Challenges
The company's portfolio remains ~85% imported, introducing meaningful FX and commodity-cost risks. Management is counteracting this through pricing agility, sourcing discipline, and a gradual shift towards local manufacturing.
Investor Takeaway
Supported by a near debt-free balance sheet and strong cash flows, IBLHL is well-positioned to expand its product range and invest in local manufacturing. Future earnings trajectory will depend on operating expense control and converting gross margin expansions into operating profit.